Dyslipidemia Among Adults With Congenital Heart Disease

Dyslipidemia in Adult Congenital Heart Disease

“…In this issue of JACC: Advances , Wu et al 7 provide real-world data on the prevalence of dyslipidemia among 186 ACHD patients by conducting a cross-sectional lipid screening study in 4 tertiary centers. Dyslipidemia was defined as TC ≥200 mg/dL, HDL-C <40 mg/dL, or non-HDL ≥130 mg/dL.…”

“… 8 Elevated non–HDL-C was also commonly found, with non–HDL-C being approximately 20 mg/dL higher among adults with simple defects compared with complex CHD in age-, sex-, and BMI-adjusted models. 7 …”

“…ACHD patients with dyslipidemia were more likely to be obese than those without dyslipidemia in this study. 7 Indeed, there seems to be a steady rise in BMI among patients with CHD between childhood and adolescence, which increases cardiovascular risk early in life. 9 Furthermore, Wu et al 7 demonstrated that patients with a simple defect were more likely to be obese compared with patients with moderate or complex defects, which could explain the different type of dyslipidemia among different CHD complexity group.…”

“… 7 Indeed, there seems to be a steady rise in BMI among patients with CHD between childhood and adolescence, which increases cardiovascular risk early in life. 9 Furthermore, Wu et al 7 demonstrated that patients with a simple defect were more likely to be obese compared with patients with moderate or complex defects, which could explain the different type of dyslipidemia among different CHD complexity group. Finally, modifiable cardiovascular health behaviors were also highly prevalent among ACHD individuals, with nearly 20% of adults with complex and moderate CHD reporting current cigarette smoking, while the majority of study participants reported low regular physical activity.…”

“…Overall, in this issue of JACC: Advances , Wu et al 7 concluded that: 1) dyslipidemia is highly prevalent among ACHD patients; 2) lipid profile differs by CHD complexity group; and 3) dyslipidemia is associated with the presence of obesity. However, this study was limited, as already acknowledged, by the small number of study participants and its cross-sectional design, which did not enable the investigators to provide follow-up data about: 1) whether measured lipid levels can predict future ASCVD risk; and 2) whether the identification of lipid profile in ACHD patients can lead to lifestyle modification and/or initiation of statin therapy.…”